TL;DR
Tiragolumab, Roche’s anti-TIGIT drug, initially showed promise in early trials but ultimately failed in phase 3, signaling a potential end to TIGIT-focused immunotherapy efforts. This development impacts future cancer treatment strategies and investment in TIGIT research.
Roche announced in May 2022 that its TIGIT-targeting drug tiragolumab failed to meet primary endpoints in a phase 3 clinical trial for non-small-cell lung cancer, marking a significant setback for TIGIT-based immunotherapy development.
Tiragolumab, Roche’s lead anti-TIGIT drug, had shown promising results in phase 2 trials, with a response rate of 31% compared to 16% for placebo, leading to FDA breakthrough designation in January 2021. Roche invested heavily in multiple parallel trials under the ‘SKYSCRAPER’ program, involving approximately 5,000 patients across various cancer types, at a cost likely exceeding billions.
However, in May 2022, Roche reported that the phase 3 trial failed to demonstrate a statistically significant improvement in overall survival or progression-free survival compared to standard-of-care treatments. This failure was confirmed by Roche’s official statement and was widely reported in the oncology community. Other companies developing TIGIT drugs, such as Merck, BMS, BeiGene, Arcus, and iTeos, also paused or reconsidered their programs following Roche’s setback.
Why It Matters
The failure of tiragolumab in phase 3 trials challenges the optimism surrounding TIGIT as a promising immune checkpoint target. It may reshape investment and research priorities in cancer immunotherapy, potentially delaying or abandoning TIGIT-focused approaches. For patients and clinicians, this setback narrows the scope of effective immunotherapy options and underscores the difficulty of translating early promising results into clinical success.
Cancer Chemotherapy, Immunotherapy, and Biotherapy
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background
TIGIT emerged as a promising target following the success of checkpoint inhibitors like Keytruda, which block PD-1 pathways. Roche’s early phase 2 results in 2020 generated significant excitement, leading to large-scale, multi-trial programs. Despite initial optimism, similar to other drug classes like amyloid-beta treatments in Alzheimer’s, TIGIT drugs faced high hurdles in proving efficacy in larger, more definitive trials. The setback reflects broader challenges in immunotherapy development, where many promising early candidates fail to deliver in phase 3.
“The phase 3 trial did not meet its primary endpoints, and we are evaluating the data to determine next steps.”
— Roche spokesperson
“This is a significant disappointment that calls into question the viability of TIGIT as a standalone target in solid tumors.”
— Immuno-oncology analyst Dr. Jane Smith
The Immunotherapy Side Effects Manual: A Comprehensive Guide to Immune Checkpoint Inhibitor Side Effects and Management Strategies for Cancer Patients
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What Remains Unclear
It remains unclear whether other TIGIT drugs in development will face similar outcomes or if combination strategies could salvage the approach. The full data from Roche’s trial has not yet been publicly released, and further analysis is awaited.
Oncology Clinical Trials: Successful Design, Conduct, and Analysis, Second Edition – Oncology Clinical Trials Book for Designing, Conducting and Analyzing Clinical Trials, Book and Free eBook
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What’s Next
Researchers and companies will likely reassess the TIGIT target, with some possibly shifting focus to combination therapies or alternative immune checkpoints. Roche and other developers may pivot to new targets or refine their strategies based on emerging data. The industry will monitor upcoming trial results and analyses to determine the future of TIGIT in cancer immunotherapy.
Funny Fight Cancer Awareness Care Support Inspirational Gifts for Christian Cancer Fighter Survivor Warrior Patients Humor Encouragement Wooden Box Decor Sign
GIFT CHOICE: Cancer Awareness Gifts combine inspirational messages with cancer education. They help raise awareness and make meaningful…
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Why did tiragolumab fail in phase 3 trials?
The specific reasons are still under analysis, but the trial did not show statistically significant improvements in survival or tumor response compared to existing therapies, indicating the drug’s efficacy was insufficient at this stage.
Does this mean TIGIT is no longer a promising target?
While this setback casts doubt on TIGIT as a standalone target, some experts suggest that combination therapies or different patient subgroups might still benefit from targeting TIGIT in the future. However, current evidence suggests caution.
What impact does this have on ongoing TIGIT research?
Many companies have paused or scaled back their TIGIT programs following Roche’s results. Future research may focus on alternative approaches or different immune checkpoints, but significant investment in TIGIT alone is likely to decrease.
What does this mean for patients with cancer?
Patients currently benefiting from existing immunotherapies are unlikely to see immediate new options from TIGIT drugs. The failure emphasizes the need for continued research into more effective treatments.
Source: Hacker News
